Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXTD74)

Drug Name
GC33 Drug Info
Synonyms RO5137382
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMXTD74

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glypican-3 (GPC3) TTJTSX4 GPC3_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glypican-3 (GPC3) DTT GPC3 5.641 5.661 6.547 5.174
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hepatocellular carcinoma
ICD Disease Classification 2C12.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glypican-3 (GPC3) DTT GPC3 5.54E-86 3 9.74
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01507168) A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma. U.S. National Institutes of Health.
2 First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.